SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.

Oncogene
Ke JiangSongshu Meng

Abstract

Triple-negative breast cancer (TNBC) is extremely aggressive and lacks effective therapy. SAM and SH3 domain containing1 (SASH1) has been implicated in TNBC as a candidate tumor suppressor; however, the mechanisms of action of SASH1 in TNBC remain underexplored. Here, we show that SASH1 was significantly downregulated in TNBC patients samples compared with other subtypes of breast cancer. Ectopic SASH1 expression inhibited, while depletion of SASH1 enhanced, the invasive phenotype of TNBC cells, accompanied by deregulated expression of MMP2 and MMP9. The functional effects of SASH1 depletion were confirmed in the chicken chorioallantoic membrane and mouse xenograft models. Mechanistically, SASH1 knockdown downregulated the phosphorylation levels of the Hippo kinase LATS1 and its effector YAP (Yes associated protein), thereby upregulating YAP accumulation together with its downstream target CYR61. Consistently, forced SASH1 expression exhibited opposite effects. Pharmacological inhibition of YAP or knockdown of YAP reversed the enhanced cell invasion of TNBC cells following SASH1 depletion. Furthermore, SASH1-induced YAP signaling was LATS1-dependent, which in reverse enhanced phosphorylation of SASH1. The SASH1 S407A mutant (ph...Continue Reading

References

Mar 23, 2010·Current Biology : CB·Meghna Das ThakurGregory D Longmore
Aug 9, 2011·The International Journal of Biochemistry & Cell Biology·Melanie MartiniKlaus-Peter Janssen
Jun 26, 2012·Biochemical and Biophysical Research Communications·Kazuyasu ShojiKensaku Mizuno
Dec 4, 2014·Acta Biochimica Et Biophysica Sinica·Peiguo ShiCeshi Chen
Mar 18, 2015·Nature·Sean PorazinskiMakoto Furutani-Seiki
Apr 22, 2015·The Journal of Clinical Investigation·Xin ZhouKun-Liang Guan
Dec 17, 2015·Nature Communications·Tackhoon KimDae-Sik Lim
Jan 6, 2016·Genes & Development·Zhipeng MengKun-Liang Guan
Jul 28, 2016·Molecular and Cellular Biology·Radhika JagannathanGregory D Longmore
Nov 11, 2016·Cell Death & Disease·Joshua T BurgessDerek J Richard
Feb 1, 2017·OncoTargets and Therapy·Xuchu GongHao Shen
Feb 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesca CitronGustavo Baldassarre
May 26, 2017·Cell Reports·Yiting QiaoMarius Sudol
Jun 7, 2017·Journal of Cell Science·Weifeng LuoDaniel Rosel
Aug 22, 2017·Experimental Cell Research·Kandis StubblefieldJohn E Shively
Jul 22, 2018·Biophysics Reviews·Joelle V F CoumansPierre D J Moens
Nov 28, 2018·Cellular and Molecular Gastroenterology and Hepatology·Fabian Christoph FrankeKlaus-Peter Janssen
Dec 20, 2018·Annual Review of Biochemistry·Shenghong MaKun-Liang Guan
Jun 9, 2019·Trends in Cancer·Philamer C CalsesAnwesha Dey
Aug 7, 2019·Developmental Cell·Yonggang Zheng, Duojia Pan

❮ Previous
Next ❯

Citations

Feb 6, 2022·Journal of Cancer Research and Clinical Oncology·Cynthia KohlThomas Papathemelis

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-seq
xenograft
co-immunoprecipitation
immunoprecipitation
light microscopy

Software Mentioned

MEME suite
SPSS
GSEA

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.